MaxCyte, Inc. MXCT
1.19 USD 0.00 (+0.00%)
Regular-session close
1.18 -0.01 -0.84%
After hours · Nov 13, 4:00 PM ET
1.12 Day range 1.20
0.643 52-week range 1.81
- YTD
- -23.23%
- 1 year
- -21.19%
News
seekingalpha.com MaxCyte, Inc. (MXCT) Q3 2026 Earnings Call Transcript MaxCyte, Inc. ( MXCT ) Q3 2026 Earnings Call November 10, 2026 8:30 AM EST Company Participants Maher Masoud - President, CEO & Executive Director Parmeet Ahuja - Chief Financial Officer Conference…
benzinga.com MaxCyte Q3 2026 Earnings Call Transcript MaxCyte (NASDAQ:MXCT) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This content is powered by Benzinga…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Longeveron (NASDAQ:LGVN) stock…
marketbeat.com MaxCyte Q3 Earnings Call Highlights MaxCyte NASDAQ: MXCT reported 49% third-quarter revenue growth and raised its 2026 revenue outlook, while announcing an agreement to acquire cell therapy materials supplier Akron Bio for $151.8…benzinga.com MaxCyte To Acquire Akron BioProducts From Arcline Investment Management For Total Consideration Of $151.8M, Comprising $105M In Cash And 20.6M MXCT Shares Worth ~$26.8M Under the terms of the agreement, MaxCyte will acquire Akron for total consideration of $151.8 million. At the close of the transaction, MaxCyte will pay $105.0 million in cash, subject to customary…
benzinga.com MaxCyte Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $10.152M Beat $7.481M Estimate MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 58.33 percent increase over losses of $(0.12) per…
globenewswire.com MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance Third Quarter and Recent Business Highlights: Reports total revenue of $10.2 million for the third quarter of 2026, including $8.2 million of core revenue and $2.0 million of SPL Program-related…
globenewswire.com MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
